Physician profile
Aidan Russo
NPI 1689259772
$5,204.82
in general payments reported to CMS, 2019-2025
24 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $464 · 2023: $799 · 2024: $1,170 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Consulting Fee: $375 · Education: $80.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.98 |
| Consulting Fee | $375.00 |
| Education | $80.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $876.04 | 2022-2025 | Tremfya |
| Incyte Corporation | $592.85 | 2022-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $559.25 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $400.47 | 2021-2025 | |
| Genzyme Corporation | $363.34 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $315.57 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $241.11 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $236.58 | 2023-2025 | Zoryve |
| Abbvie INC. | $210.51 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $208.85 | 2023-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $186.01 | 2022-2025 | |
| Amgen INC. | $160.77 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.87 | 2022-2025 | Cabtreo, Jublia, Arazlo |
| Galderma Laboratories, L.P. | $109.08 | 2022-2025 | Nemluvio |
| Ucb, INC. | $107.43 | 2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $104.74 | 2025 | Vtama |
| Lilly USA, LLC | $98.17 | 2021-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $86.25 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $73.56 | 2023-2024 | |
| Mylan Institutional INC. | $51.33 | 2023 | Hulio, Fulphila |
| Epi Health, LLC | $47.27 | 2022 | |
| Lnhc, INC | $21.36 | 2025 | Zelsuvmi |
| Botanix Sb INC | $18.88 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $15.53 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aidan Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.